Table 5. Costs according to CD4 level, WHO stages, distance and revenues.

		Outpatients				Inpatients
		(n = 280)				(n = 40)
	Direct	Indirect	p	Total	Direct	Indirect	p	Total
	costs	costs		costs	costs	costs		costs
CD4
≤ 200	7.7	9.7	NS	17.5	51.0	189.0	NS	240.0
	(5.8–9.6)	(7.3–12.1)		(13.7–21.2)	(34.0–68.0)	(116.1–261.9)		(157.8–322.2)
> 200	11.8	11.4		23.3	52.1	75.1		127.3
	(7.9–15.8)	(8.7–14.1)		(17.4–29.1)	(11.4–92.8)	(1.7–148.6)		(42.8–211.8)
WHO
stage 1–2	12.6	11.1	NS	23.7	37.7	69.7	<0.01	107.5
	(5.1–20.0)	(7.4–14.1)		(14.3–33.2)	(8.5–66.9)	(17.9–121.5)		(48.6–166.3)
stage 3–4	8.90	10.3		19.2	55.7	201.0		257.9
	(7.0–10.7)	(8.3–12.4)		(15.7–22.7)	(37.6–73.7)	(123.4–280.2)		(169.8–346.0)
Distance
≤100km	3.26	6.1	<0.01	6.19	53.6	212.2	NS	265.9
	(2.2–4.0)	(5.2–7.1)		(5.2–7.1)	(31.3–75.9)	(113.2–311.3)		(154.7–377.0)
>100 km	21.0	18.2		18.2	48.2	116.3		164.6
	(16.1–26.0)	(13.9–22.6)		(13.9–22.6)	(26.7–69.7)	(47.6–185.1)		(86.2–243.0)
Income
≤100$	6.8	7.1	<0.01	14.0	55.1	175.0	NS	230.1
	(5.4–8.2)	(5.9–8.2)		(11.8–16.1)	(34.5–75.6)	(89.5–260.4)		(133.5–326.7)
>100$	15.2	17.4		32.6	43.9	158.1		202.1
	(9.7–20.7)	(12.7–22.0)		(23.8–41.4)	(21.7–66.1)	(64.4–251.9)		(99.9–304.3)

Mean costs and 95% confidence interval (95%CI); US dollars (US$): 1 = 8500kip; CD4: cells/mm³